MEETIN INFORMATION - AP VALVES · MEETIN INFORMATION August 17 August ... Hyo-Soo Kim, MD Myeong-Ki Hong, MD ... Mao-Shin Lin, Kyung Woo Park, Jian (James) Ye Royal Victoria Hospital,

MEETING INFORM

ATION / FACULTYMEETING INFORMATION

　 August 17 August 18 August 19

Scientific Program 6:00PM ~ 8:00PM 7:30AM ~ 5:30PM 7:30AM ~ 3:50PM

Registration BoothFaculty LoungePreview Room

CVRF Booth

4:00PM ~ 8:30PM 6:30AM ~ 5:30PM 6:30AM ~ 4:00PM

Exhibition 　- 8:00AM ~ 5:30PM 8:00AM ~ 4:00PM

FACULTY

International FacultyElena AikawaBrigham and Women's Hospital, Harvard Medical School, USA

Motoharu ArakiSaiseikai Yokohama-City Eastern Hospital, Japan

Rohan B BhagwandeenJohn Hunter Hospital Newcastle Australia, Australia

Ravinay BhindiRoyal North Shore Hospital, Australia

Philipp BlankeUniversity of British Columbia & St. Paul's Hospital, Canada

Jason Leung Kwai ChanQueen Elizabeth Hospital, Hong Kong, China

Kam Tim ChanQueen Elizabeth Hospital, Hong Kong, China

Mao ChenWest China Hospital, China

Boron CW ChengQueen Elizabeth Hospital, Hong Kong, China

Gary Shing-Him CheungPrince of Wales Hospital , Hong Kong, China

Paul TL ChiamMount Elizabeth Hospital, Singapore

Guo Sheng FuSir Run Run Shaw Hospital, China

Eberhard GrubeUniversity Hospital Bonn, Germany

Kentaro HayashidaKeio University School of Medicine, Japan

Jimmy Kim Fatt HonNational University Hospital, Singapore

Paul Hsien-Li KaoNational Taiwan University Hospital, Taipei, Taiwan

Nobuyuki KomiyamaSt. Luke's International Hospital, Japan

Xiangqing KongNanjing Medical University, China

Cheung Chi Simon LamQueen Mary Hospital, Hong Kong, China

Michael Kang-Yin LeeQueen Elizabeth Hospital, Hong Kong, China

Mao-Shin LinNational Taiwan University Hospital, Taiwan

Xianbao LiuThe Second Affiliated Hospital of Zhejiang University, China

Vincent LukQueen Elizabeth Hospital, Hong Kong, China

Ganesh ManoharanRoyal Victoria Hospital, United Kingdom

Edgar Lik-Wui TayNational University Heart Centre, Singapore

Yangmeng Tian Fu Wai Hospital, China

Tetsuya TobaruSakakibara Memorial Hospital, Japan

Darren L. WaltersPrince Charles Hospital, Australia

Moyang Wang Fu Wai Hospital, China

Yuan Wang Fu Wai Hospital, China

Course DirectorsJohn Graydon Webb, MD Eberhard Grube, MD Runlin Gao, MD Seung-Jung Park, MD

Course Co-DirectorsRosli Mohd Ali, MD Kentaro Hayashida, MD Paul Hsien-Li Kao, MD Michael Kang-Yin Lee, MD Ian T. Meredith AM, MD Edgar Lik-Wui Tay, MD

Jian-an Wang, MD Bo Xu, MD Hyo-Soo Kim, MD Myeong-Ki Hong, MD Jung-Min Ahn, MD

Learning Objectives• Understand the Concept and Advances in Percutaneous Valve Implantation Technology • Assess the Imaging Modalities Available for Diagnosis of Valvular Heart Disease • Acquire the Skills Necessary to Perform Transcatheter Valve Therapies • Describe Current and Future Therapeutic Options for Valvular Heart Disease • Discuss Evaluation and Management of Patients with Valvular Heart Disease • Address Controversial Issues in Management of Heart Valve Disease • Identify When to Refer Patients for Surgery/Intervention • Discuss the Setting-up of Heart Team for Valve Implantation

Program Sponsorship and SupportAP VALVES is sponsored by CardioVasucular Research Foundation (CVRF) and Asan Medical Center (Seoul, Korea) and partially funded by educational grants from commercial supporters. The CardioVascular Research Foundation wishes to extend special appreciation to Clinical Research Center for Ischemic Heart Disease for their continued support to our programs.

Operating Hours

3

FACULTYFACULTY

Kyung-Hee KimSejong General Hospital

Kyung-Hwan KimSeoul National University Hospital

Won-Jang KimCHA Bundang Medical Center, CHA University

Young-Guk KoSeverance Hospital

Yoon Seok KohThe Catholic University of Korea, Seoul St. Mary’s Hospital

Bon-Kwon KooSeoul National University Hospital

Ohchoon KwonDaegu Catholic University Medical Center

Bong-Ki LeeKangwon National University Hospital

Cheol Whan LeeAsan Medical Center

Jae Won LeeAsan Medical Center

Jae-Hwan LeeChungnam National University Hospital

Jin Bae LeeDaegu Catholic University Medical Center

Jong-Young LeeKangbuk Samsung Hospital

Nae Hee LeeSoonChunHyang University Hospital Bucheon

Pil Hyung LeeAsan Medical Center

Sang Gon LeeUlsan University Hospital

John Graydon WebbSt. Paul's Hospital, Canada

Randolph Hung-Leung WongPrince of Wales Hospital, Hong Kong, China

Yongjian WuFu Wai Hospital, China

Bo XuFu Wai Hospital, National Center for Cardiovascular Diseases, China

Jian (James) YeSt. Paul's Hospital, University of British Columbia, Canada

Alan C. YeungStanford University School of Medicine, USA

Wei-Hsian YinCheng-Hsin General Hospital, Taiwan

Wenjia Zhang Fu Wai Hospital, China

Korean FacultyHyuk AhnSeoul National University Hospital

Jung-Min AhnAsan Medical Center

Byung Chul ChangSeverance Hospital

Kiyuk ChangThe Catholic University of Korea, Seoul St. Mary’s Hospital

Mineok ChangThe Catholic University of Korea, Seoul St. Mary’s Hospital

Seung Hyuk ChoiSamsung Medical Center

Seung-Whan LeeAsan Medical Center

Duk-Woo ParkAsan Medical Center

Gyung-Min ParkThe Catholic University of Korea, Daejeon St. Mary's Hospital

Ha Wook ParkThe Catholic University of Korea, Daejeon St. Mary's Hospital

Hyun Woo ParkSoon Chun Hyang University Bucheon Hospital

Jinsik ParkSejong General Hospital

Kyung Woo ParkSeoul National University Hospital

Pyo Won ParkSamsung Medical Center

Seung-Jung ParkAsan Medical Center

Sung-Ji ParkSamsung Medical Center

Seung-Woon RhaKorea University Guro Hospital

Chi Young ShimSeverance Hospital

Ji-Yeon SimAsan Medical Center

Jae-Kwan SongAsan Medical Center

Jong-Min SongAsan Medical Center

Young Jin ChoiSejong General Hospital

Suk Jung ChooAsan Medical Center

Woo-Baek ChungYeouido St. Marys Hospital

Ran HeoAsan Medical Center

Geu Ru HongSeverance Hospital

Myeong-Ki HongSeverance Hospital

Seung-Ho HurKeimyung University Dongsan Medical Center

Jae-Sik JangInje University Pusan Paik Hospital

Sung-Ho JungAsan Medical Center

Do-Yoon KangAsan Medical Center

Duk-Hyun KangAsan Medical Center

Se Hun KangAsan Medical Center

Hyo-Soo KimSeoul National University Hospital

Ju Han KimChonnam National University Hospital

Jun Bum KimAsan Medical Center

June Hong KimPusan National University Yangsan Hospital

5

PROGRAMPROGRAM

Wednesday, 17Main Arena, Vista Hall, B2

Evening SymposiumFrom Bench to Bedside6:00 PM ~ 8:00 PMModerators: Eberhard Grube, Seung-Jung Park, Jae-Kwan Song, John Graydon WebbPanelists: Jung-Min Ahn, Elena Aikawa, Kyung-Hee Kim, Darren L. Walters, Jian (James) Ye, Alan C. Yeung

Part I: From Bench

6:00 PM Novel Aspects in Calcific Aortic Valve ResearchElena Aikawa

6:15 PM Animal Model of Mitral Regurgitation - What We Have LearnedKyung-Hee Kim

6:30 PM Aortic Cusp Asymmetry and Adaptation in Aortic RegurgitationJae-Kwan Song

6:45 PM Panel Discussion with Q & A

Part II: To Bedside

6:50 PM Current Status of TAVR: High/Intermediate and Lower RiskJung-Min Ahn

7:00 PM Surgeon's Role in the Era of Transcatheter Valve TreatmentJian (James) Ye

7:10 PM Minimalism in TAVRJohn Graydon Webb

7:20 PM Evolving Trends in Complications After TAVREberhard Grube

7:30 PM Next Issue: How to Manage Failed Transcatheter Heart ValveAlan C. Yeung

7:40 PM Panel Discussion with Q & A

Thursday, 18Main Arena, Vista Hall, B2

Breakfast MeetingOutcomes Across Valves: Review of Current Data7:30 AM ~ 8:30 AMModerators: Eberhard Grube, John Graydon WebbPanelists: Jung-Min Ahn, Kentaro Hayashida, Hyo-Soo Kim, Michael Kang-Yin Lee, Xianbao Liu, Seung-Jung Park, Darren L. Walters

7:30 AM SAPIEN 3: PARTNER 2 and Real-World RegistryJohn Graydon Webb

7:38 AM Evolut REberhard Grube

7:46 AM LotusHyo-Soo Kim

7:54 AM VENUS A China TrialXianbao Liu

8:02 AM Edwards CENTERA Self-Expanding THV System - Initial ExperienceDarren L. Walters

8:10 AM Current Status of TAVI in JapanKentaro Hayashida

8:18 AM AP TAVR RegistryJung-Min Ahn

8:26 AM Panel Discussion with Q & A

Plenary SessionLive Case Session I8:30 AM ~ 10:00 AMModerators: Seung-Jung Park, John Graydon WebbDiscussants: Mao Chen, Boron CW Cheng, Hyo-Soo Kim, Young-Guk Ko, Xianbao Liu, Tetsuya Tobaru, Alan C. Yeung, Wei-Hsian Yin

Fu Wai Hospital, China8:30 AM 1st Operator: Yongjian Wu Operators: Yue-Jin Yang, Wei Wang

Opening & Lecture #110:00 AM ~ 11:30 AMModerators: Eberhard Grube, Seung-Jung ParkPanelists: Elena Aikawa, Philipp Blanke, Duk-Hyun Kang, Hyo-Soo Kim, Michael Kang-Yin Lee, Jae-Kwan Song, Alan C. Yeung

10:00 AM Opening RemarkSeung-Jung Park

Featured Lectures

10:05 AM New View on Pathogenesis of Cardiovascular CalcificationElena Aikawa

10:15 AM TAVR in Lower RiskEberhard Grube

10:25 AM Durability of THV and Management of Failed THVJohn Graydon Webb

10:35 AM Frailty Assessment and How to Define Futile TAVRAlan C. Yeung

10:45 AM TAVR Imaging: Preprocedural CT Imaging for Transcatheter Aortic Valve ReplacementPhilipp Blanke

10:55 AM Panel Discussion with Q & A

Low Gradient Severe AS

11:00 AM Diagnosis and Physiologic Understanding of Low Gradient Severe ASJae-Kwan Song

11:10 AM Early TAVR/SVR or Watchful Waiting?Duk-Hyun Kang

11:20 AM Panel Discussion with Q & A

Live Case Session II11:30 AM ~ 12:30 PMModerators: Seung-Jung Park, Alan C. YeungDiscussants: Motoharu Araki, Rohan B Bhagwandeen, Kam Tim Chan, Kiyuk Chang, Paul TL Chiam, June Hong Kim, Jae-Hwan Lee, Michael Kang-Yin Lee, Edgar Lik-Wui Tay, Darren L. Walters

Asan Medical Center, Seoul, Korea11:30 AM Case #1 1st Operator: Jung-Min Ahn 2nd Operator: Pil Hyung Lee Case #2 1st Operator: John Graydon Webb 2nd Operator: Kentaro Hayashida 3rd Operator: Se Hun Kang

Echo Interpreter: Ran Heo CT Interpreter: Do-Yoon Kang

Lunchtime ActivityCase Presentations12:30 PM ~ 2:00 PMModerators: Eberhard Grube, Seung-Jung ParkPanelists: Motoharu Araki, Philipp Blanke, Kam Tim Chan, Boron CW Cheng, Paul TL Chiam, Michael Kang-Yin Lee,Jian (James) Ye

12:30 PM TAVI in Patients with Difficult Vascular AccessYoung-Guk Ko

12:40 PM First Transcatheter Valve-in-Valve Implantation in an Apico-Aortic Valve Conduit Jian (James) Ye

12:50 PM TAVI as an Urgent Salvage Treatment Modality for a Patient with Multi-Organ Failure on Severe ASHyo-Soo Kim

1:00 PM Reduction of Functional MR by Mitral Loop Cerclage May also Contribute to Reversion of Atrial Fibrillation to Normal Sinus Rhythm?June Hong Kim

7

PROGRAMPROGRAM

1:10 PM Transapical Valve-in-Valve for Dysfunctional Mitral Bioprosthesis: Sapien XT vs. Lotus ValvesWei-Hsian Yin

1:20 PM Ectopic TAVI Where the Core Valve was Deployed at the Thoracic Aorta and Late OutcomeKam Tim Chan

1:30 PM TAVI for A Patient with Severe CalcificationKentaro Hayashida

1:40 PM TTE Assisted MitraClip Procedure in a Patient with Difficult TEEBoron CW Cheng

Plenary SessionLecture #22:00 PM ~ 4:00 PMModerators: Eberhard Grube, Hyo-Soo KimPanelists: Jung-Min Ahn, Kam Tim Chan, Mao Chen, Jae-Kwan Song, Darren L. Walters, Alan C. Yeung, Wei-Hsian Yin

Post TAVR Management

2:00 PM Monitoring Conduction Disturbance and Avoiding Permanent PacemakerEberhard Grube

2:10 PM Early Discharge Check List to Be MinimalistAlan C. Yeung

2:20 PM Assessment of PVL and Prognostic ImpactKam Tim Chan

2:30 PM Infective EndocarditisDarren L. Walters

2:40 PM Optimal Antithrombotic Treatment and How Long?Hyo-Soo Kim

2:50 PM Valve Thrombosis: Clinical Significance and TreatmentWei-Hsian Yin

3:00 PM Panel Discussion with Q & A

Bicuspid

3:20 PM Incidence, Genetics, and Clinical Features: Deep Dive in Bicuspid Aortic Valve DiseaseJae-Kwan Song

3:30 PM Bicuspid Valve: The China Experience with the Venus ValveMao Chen

3:40 PM Bicuspid TAVR RegistryJung-Min Ahn

3:50 PM Panel Discussion with Q & A

Live Case Session III4:00 PM ~ 5:30 PMModerators: Eberhard Grube, Seung-Jung ParkDiscussants: Ravinay Bhindi, Myeong-Ki Hong, Paul Hsien-Li Kao, Yoon Seok Koh, Xiangqing Kong, Cheung Chi Simon Lam, Mao-Shin Lin, Kyung Woo Park, Jian (James) Ye

Royal Victoria Hospital, UK4:00 PM 1st Operator: Ganesh Manoharan

Friday, 19Main Arena, Vista Hall, B2

Breakfast MeetingMitral Valve Therapeutics7:30 AM ~ 8:30 AMModerators: Eberhard Grube, Darren L. Walters, John Graydon WebbPanelists: Philipp Blanke, Kam Tim Chan, Boron CW Cheng,Seung Hyuk Choi, Myeong-Ki Hong, Seung-Jung Park, Wei-Hsian Yin

7:30 AM Mitraclip - How Do We Best Measure Residual MR Post Procedure?Darren L. Walters

7:40 AM Preprocedural CT Imaging for Transcatheter Mitral Valve ReplacementPhilipp Blanke

7:50 AM Initial Experience with Transcatheter Mitral Valve Replacement - The Tendyne SystemDarren L. Walters

8:00 AM Update on Medtronic Intrepid Transcatheter Mitral Valve ReplacementEberhard Grube

8:10 AM Transcatheter Mitral Valve Implantation: OverviewJohn Graydon Webb

8:20 AM Panel Discussion with Q & A

Plenary SessionLive Case Session IV8:30 AM ~ 9:30 AMModerators: Hyuk Ahn, Byung Chul ChangDiscussants: Kentaro Hayashida, Jimmy Kim Fatt Hon, Ohchoon Kwon, Jae Won Lee, Pyo Won Park, Wei Wang, Randolph Hung-Leung Wong

Asan Medical Center, Seoul, Korea8:30 AM Case #3 1st Operator: Jian (James) Ye 2nd Operator: Suk Jung Choo 3rd Operator: Jun Bum Kim 4th Operator: Jung-Min Ahn

Echo Interpreter: Ran Heo CT Interpreter: Do-Yoon Kang

Lecture #39:30 AM ~ 10:30 AMModerators: John Graydon Webb, Alan C. YeungPanelists: Young Jin Choi, Paul Hsien-Li Kao, Michael Kang-Yin Lee, Darren L. Walters, Wei-Hsian Yin

Challenging Situation I

9:30 AM Low Coronary Ostium with Narrow or Wide SinusAlan C. Yeung

9:40 AM Severe LV DysfunctionDarren L. Walters

9:50 AM Iliofemoral Artery Disease: Borderline or SevereMao-Shin Lin

10:00 AM Valve-in-Valve: Mitral ValveWei-Hsian Yin

10:10 AM Role of Surgical AVR in TAVI EraPyo Won Park

10:20 AM Panel Discussion with Q & A

Live Case Session V10:30 AM ~ 11:15 AMModerators: Darren L. Walters, Alen C. YeungDiscussants: Ravinay Bhindi, Jason Leung Kwai Chan, Gary Shing-Him Cheung, Seung Hyuk Choi, Young Jin Choi, Guo Sheng Fu, Seung-Ho Hur, Mao-Shin Lin

The Catholic University of Korea, Seoul St. Mary's Hospital10:30 AM Evolut R 1st Operator: Kiyuk Chang 2nd Operator: Eberhard Grube Operators: Yoon Seok Koh, Woo-Baek Chung, Ha Wook Park, Jaeho Byeon

Lecture #411:15 AM ~ 12:30 PMModerators: Myeong-Ki Hong, John Graydon WebbPanelists: Jung-Min Ahn, Nobuyuki Komiyama, Edgar Lik-Wui Tay, Randolph Hung-Leung Wong, Jian (James) Ye

Challenging Situation II

11:15 AM Valve-in-Valve: Aortic ValveJian (James) Ye

11:25 AM Trans-Aortic TAVI: Choices of Surgical AccessRandolph Hung-Leung Wong

11:35 AM Vascular Access and Managing ComplicationEdgar Lik-Wui Tay

11:45 AM TAVI for Pure Aortic InsufficiencyJian (James) Ye

9

FLOOR PLAN / EXHIBITIONPROGRAM

11:55 AM Panel Discussion with Q & A

Stroke

12:05 PM Etiology, Temporal Trend and Risk FactorsEdgar Lik-Wui Tay

12:15 PM Cerebral Embolic Protection During TAVREberhard Grube

12:25 PM Panel Discussion with Q & A

Lunchtime ActivityCase Presentations12:30 PM ~ 2:00 PMModerators: Seung-Jung Park, Alan C. YeungPanelists: Ravinay Bhindi, Jason Leung Kwai Chan, Gary Shing-Him Cheung, Seung Hyuk Choi, Myeong-Ki Hong, Paul Hsien-Li Kao, Nobuyuki Komiyama, Edgar Lik-Wui Tay, Darren L. Walters, Yongjian Wu

12:30 PM Emergent TAVI in Cardiogenic Shock due to Severe ASMyeong-Ki Hong

12:40 PM Is It Suitable for TAVI?: Using TAVI in Large Bicuspid Aortic Valve Under ECMO Support and Close the Para-Leak with Plugs at the EndJason Leung Kwai Chan

12:50 PM Trans-Aortic TAVI: A Viable AlternativeRandolph Hung-Leung Wong

1:00 PM CENTERA Valve-Release Mechanism Failure Due to Narrow Aortic Arch Dimension-Successful ManagementDarren L. Walters

1:10 PM Usefulness of a Rigid Table Mount System During Transcatheter Aortic Valve Implantation with Direct Aortic ApproachNobuyuki Komiyama

1:20 PM TAVI in the Obese Bicuspid Patient Ravinay Bhindi

1:30 PM TAVI in a Patient with Coronary Stent in Left Main OstiumEdgar Lik-Wui Tay

Plenary SessionLive Case Session VI2:00 PM ~ 3:30 PMModerators: Eberhard Grube, Myeong-Ki HongDiscussants: Paul Hsien-Li Kao, Ju Han Kim, Kyung-Hwan Kim, Won-Jang Kim, Nobuyuki Komiyama, Vincent Luk, Duk-Woo Park, Edgar Lik-Wui Tay, Yongjian Wu

Seoul National University Hospital, Korea2:00 PM Lotus Valve 1st Operator: Hyo-Soo Kim

Asan Medical Center, Seoul, Korea2:45 PM Case #4 1st Operator: Seung-Jung Park 2nd Operator: Alan C. Yeung 3rd Operator: Jung-Min Ahn 4th Operator: Se Hun Kang

Echo Interpreter: Ran Heo CT Interpreter: Do-Yoon Kang

Lecture #5 & Closing3:30 PM ~ 3:50 PMModerator: Eberhard Grube

3:30 PM Future in Transcatheter Heart Valve TreatmentDuk-Woo Park

3:45 PM Closing Remark and Brief Wrap-upEberhard Grube

FLOOR PLAN / EXHIBITION

Company Name Booth no. Company Name Booth no.

Boston Scientific 1-2 Medtronic Korea plc. 6-7

Venus Medtech 3Edwards Lifesciences Korea

Co., Ltd.8-9

Siemens Healthcare 4 Pfizer Pharmaceutical Korea Ltd. 10

Mitsubishi Tanabe Pharma Korea / CJ HealthCare

5 AstraZeneca Korea 11

EXHIBITION

11

ALPS※ in Lipitor

Pfizer tower, 110, Toegye-ro, Jung-gu, Seoul, Korea 04631 Tel: +82-2-317-2114 or +82-80-022-1400 (Toll-free), Homepage:www.pfizer.co.kr, Medical information for Healthcare Professionals: +82-80-210-2114 (Tel), [email protected] (e-mail).

ATORVASTATINL A N D M A R K P R O G R A M S

PP-LIP-KOR-0254-Jul2016

Use Statins to Treat risks1†,not just cholesterol

P o w e r

E v i d e n c e

C o n f i d e n c e

*

**

***

Reference 1. Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC et al.2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1-S45 2. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipidlowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol 2004;44:1772-79. 3. Sever PS et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre, randomized, controlled trial. Lancet 2003;361:1149-58. 4. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. 5. Athyros VG et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus “usual” care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220-28. 6. Schwartz GG et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001;285:1711-18. 7. Cannon CP et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. 8. LaRosa JC et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35. 9. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80mg versus 10mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97(1):61-67. 10. Data on File, Pfizer 11. IMS Patient Years Experience

[APPEARANCE] white, round, film-coated tablets. [COMPOSITION] atorvastatin calcium trihydrate 10.85mg, 21.70mg, 43.40mg, 86.80mg (equivalent to atorvastatin 10mg, 20mg, 40mg, 80mg) [INDICATIONS] Atorvastatin is indicated to reduce the risk of myocardial infarction, revascularization procedure, angina and stroke in adult patients with multiple risk factor but without clinically evident CHD; to reduce the risk of myocardial infarction and stroke in patients with type 2 diabetes and without clinically evident CHD but with multiple risk factor; to reduce the risk of nonfatal myocardial infarctions, fatal and nonfatal stroke, revascularization procedures, hospitalization for CHF and angina in adult patients with clinically evident CHD. Atorvastatin adjunct to diet in boys and postmenarchal girls and is indicated for administration by heterozygous familial hypercholesterolemia in pediatric patients (10-17 years of age) [DOSAGE AND METHOD OF ADMINISTRATION] The dosage of Lipitor is 10 to 80mg once a day. Doses may be given at any time of day and with or without food. [PRECAUTIONS FOR USE] Warnings Atorvastatin therapy should be discontinued if a significant increase of creatine kinase (CK) level is observed or if myopathy is diagnosed or suspected. In addition, atorvastatin therapy should be temporarily withheld or discontinued in any patient with an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (e.g., severe acute infection, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders, and uncontrolled seizures). (Please refer to Myopathy/Rhabdomyolysis section in General Precautions.) Contraindications 1) In patients with hypersensitivity to atorvastatin or any component of this medication 2) Active liver disease or unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal 3) Myopathy 4) During pregnancy or in women of child-bearing potential, while breast-feeding 5) Pediatric patients younger than 10 years old 6) Because of lactose contained in this drug, it should not be administered to the patients with hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Adverse Events Most frequently reportes adverse events reported in various clinical trials include, malaise, dyspepsia, nausea, flatulence, constipation, diarrhea, abdominal pain, headache, insomnia and myalgia regardless of casual relationship General Precautions Some evidence suggests that statins as a class raise blood glucose and in some pa-tients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/L, BMI>30kg/m2, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines [LATEST REVISION DATE] 2016.06.02 Please refer to your local product labeling for full prescribing information.

Safety info LIPITOR® (atorvastatin calcium) tablets are contraindicated in patients with a known hypersensitivity to any component of this product; in patients with active liver disease or unexplained persistent elevations of hepatic transaminases.

* Powerful LDL reduction of > 50% 1 ** Proven CV outcomes across a broad range of patients 2-8 *** An established safety profile and experience you can trust 9-11 † Major Cardiovascular Event : Death from CHD, nonfatal non-procedure-related myocardial infarction, resuscitation after cardiac arrest, or fatal or nonfatal stroke. ※ ALPS (Atorvastatin Landmark ProgramS)? Extensively studied in more than 400 ongoing and completed clinical trials including more than 80,000 patients worldwide.10